S100A9 and rheumatoid arthritis: These findings suggest that inhibiting S100A12, S100A8, and S100A9, could be an effective therapeutic strategy for osteoclast-related disease, such as the erosive form of RA and the systemic bone loss in various inflammatory conditions.